Home Education Advancements in GU Cancer Immunotherapy Treatment Series

Advancements in Genitourinary Cancer Immunotherapy Treatment Series

Series Overview

Based on the demonstrated need for additional education in this area, the AUA has developed the Advancements in Genitourinary Cancer Immunotherapy Treatment Series which is comprised of a variety of activities, including four live webinars, webcasts and podcasts on current immunotherapeutic agents for the treatment of GU cancer plus three podcast addressing the barriers to immunotherapy treatment of GU cancer.

All activities are complimentary. Maximum of 5.5 AMA PRA Category 1 Credits

A New Class of Drugs

A Focus on Bladder Cancer

A Focus on Kidney Cancer

A Focus on Prostate Cancer

Breaking Down the Barriers: Incorporating New IO Therapies: Biomarkers

Breaking Down the Barriers: Incorporating New IO Therapies: Managing Patient Side Effects

Breaking Down the Barriers: Incorporating New IO Therapies: How to Properly Administer IO Therapies in an Infusion Suite

Course Director

Costas D. Lallas, MD, FACS

Target Audience

This activity is designed for urologists, residents, advanced practice provider, non-urologists (MD or DO), and nurses.  This activity may also be of interest to other clinicians and health care professionals involved in the treatment of patients impacted by GU.

Course Purpose

The course purpose of this educational activity is to improve clinicians' understanding of current immunotherapeutic agents for the treatment of GU cancer and to increase their ability to improve patient outcomes and the management of adverse events.

The Breaking Down the Barriers: Incorporating New IO Therapies Podcast Series is intended to build upon knowledge gained on immunotherapy treatment to inform the audience of the associated barriers of immunotherapies.

Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Restate the role of the immune system in cancer prevention and elimination.
  2. Discuss the effects of immune system checkpoint inhibitors on the immunosuppressive activity of tumor cells.
  3. Review clinical investigations into the efficacy of immune system checkpoint inhibitors in the treatment of GU cancers.
  4. Identify current IO treatment barriers associated with biomarkers, managing patient side effects and the proper administration of IO therapies in an infusion suite.

CME Information


The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American Urological Association designates this live activity and enduring material for a maximum of 5.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Other Learners

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence-Based Content

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous and free of commercial bias.

AUA Disclosure Policy

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual's relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstration.
  • Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices

It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


This educational series is supported by independent educational grants from:


Bristol-Myers Squibb

Merck & Co., Inc.

Patient Education Materials

To encourage and support the participant's care of their patients, this activity will provide a resource from the Urology Care Foundation. The Immunotherapy Symptom Assessment Tool is available for download and for order.

For Order